Open Access

REVIEW

Anticancer Activity of Novel NF-kB Inhibitor DHMEQ by Intraperitoneal Administration

by

* Department of Molecular Target Medicine, Aichi Medical University, Nagakute, Japan
† Department of Pathophysiology, Poznan University of Medical Sciences, Poznan, Poland
‡ Scientific Research Institute of Oncology, Bashkortostan State Medical University, Ufa, Russia

Oncology Research 2020, 28(5), 541-550. https://doi.org/10.3727/096504020X15929100013698

Abstract

There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF- B inhibitor named dehydroxymethylepoxyquinomicin (DHMEQ) was discovered in 2000. This compound was designed based on the structure of epoxyquinomicin isolated from a microorganism. It was shown to be a specific inhibitor that directly binds to and inactivates NF- B components. Until now, DHMEQ has been used by many scientists in the world to suppress animal models of cancer and inflammation. Especially, it was shown to suppress difficult cancer models, such as hormone-insensitive breast cancer and prostate cancer, cholangiocarcinoma, and multiple myeloma. No toxicity has been reported so far. DHMEQ was administered via the intraperitoneal (IP) route in most of the animal experiments because of its simplicity. In the course of developmental studies, it was found that IP administration never increased the blood concentration of DHMEQ because of the instability of DHMEQ in the blood. It is suggested that inflammatory cells in the peritoneal cavity would be important for cancer progression, and that IP administration, itself, is important for the effectiveness and safety of DHMEQ. In the present review, we describe mechanism of action, its in vivo anticancer activity, and future clinical use of DHMEQ IP therapy.

---

Keywords

---